Galecto Expected Upcoming Milestones; Top-Line Results From Phase 2b GALACTIC-1 Trial In Mid-2023; Interim Safety Data From Phase 2a GALLANT-1 Trial By Q1 2023; Initiation Of Phase 2 Investigator-Initiated GB1211 Oncology Trial in 2023
Galecto Expected Upcoming Milestones; Top-Line Results From Phase 2b GALACTIC-1 Trial In Mid-2023; Interim Safety Data From Phase 2a GALLANT-1 Trial By Q1 2023; Initiation Of Phase 2 Investigator-Initiated GB1211 Oncology Trial in 2023
Galecto预计即将到来的里程碑；2023年年中2b期Galaxy-1试验的主要结果；2023年第一季度2a期GARANT-1试验的临时安全数据；2023年启动由调查员发起的第二阶段GB1211肿瘤学试验
Expected Upcoming Milestones
预期即将到来的里程碑
- Top-line results from Phase 2b GALACTIC-1 trial (IPF) in mid-2023.
- Interim safety data from Phase 2a GALLANT-1 trial (NSCLC) by Q1 2023.
- Initiation of Phase 2 investigator-initiated GB1211 oncology trial (melanoma and HNSCC) by Providence Cancer Institute in 2023.
- 2023年年中2b期银河1号试验(IPF)的主要结果。
- 到2023年第一季度2a期GARANT-1试验(NSCLC)的临时安全数据。
- 普罗维登斯癌症研究所于2023年启动由研究人员发起的2期GB1211肿瘤学试验(黑色素瘤和HNSCC)。
"The recent release of positive results from two clinical trials, our Phase 1b/2a GULLIVER-2 trial in decompensated liver cirrhosis and our Phase 2a MYLOX-1 trial in myelofibrosis, has created significant momentum for Galecto and our team," said Galecto CEO Hans T. Schambye, M.D., Ph.D. "Galectin-3 and LOXL2 play a central role in fueling key pathological pathways in fibrosis, and the encouraging results from both of these trials provides further evidence and strengthens our belief that the inhibition of galectin-3 and LOXL2 are crucial to reducing fibrosis and potentially modifying disease. We look forward to 2023, where we expect to announce top-line results from our Phase 2b GALACTIC-1 trial in idiopathic pulmonary fibrosis (IPF) in mid-2023 and our Phase 2a GALLANT-1 trial in non-small cell lung cancer (NSCLC) in the second half of 2023."
Galecto公司首席执行官汉斯·T·尚拜博士说：“最近公布的两项临床试验的阳性结果，即我们治疗失代偿性肝硬变的1b/2a期Gulliver-2试验和我们治疗骨髓纤维化的2a期MYLOX-1试验，为Galecto公司和我们的团队创造了巨大的动力。”Galectin-3和LOXL2在促进纤维化的关键病理途径方面发挥着核心作用，这两个试验的令人鼓舞的结果提供了进一步的证据，并坚定了我们的信念，即抑制Galectin-3和LOXL2对于减少纤维化和潜在地改善疾病至关重要。我们期待着2023年，届时我们预计将在2023年年中宣布我们治疗特发性肺纤维化(IPF)的2b期Galaxy-1试验的主要结果，并在2023年下半年宣布我们治疗非小细胞肺癌(NSCLC)的2a期Galant-1试验的主要结果。